Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether treating upper airway with intranasal corticosteroids in children with allergic rhinitis and no asthma may bring favors in reducing lower airway inflammation and improving small airway function.
Type of study :
This is a prospective randomized,double-blind, placebo-controlled study , to clarity whether treating upper airway with intranasal corticosteroids in children with allergic rhinitis may bring favors in reducing elevated lower airway inflammation，improving airway reactivity and airway resistance.
Methods :
The children with allergic rhinitis accompanied lower airway inflammation such as elevated percentage of eosinophil in induced sputums and/or higher level of fractional exhaled nitric oxide(FeNO) are recruited.By using a random digit table, eligible subjects were randomized into one of two groups,to receive budesonide nasal spray (BUD group) or nasal placebo(placebo group), 1 spray/nostril, 2 times/day, for three consecutive months observation. The following measurements were performed: skin prick test (SPT), peripheral blood cells five-classification test, serum total immunoglobulin E (IgE) and specific IgE of common inhalant allergens testing, nasal lavage and inflammatory cells classification ，pulmonary function test, bronchial provocation test，airway resistance measured by impulse oscillation technique. Meanwhile,history of all subjects were collected, visual analogue scale，rhinitis symptoms scores and rhinoconjunctivitis quality of life questionnaire (RQLQ) scores were evaluated. Symptom scores and laboratory examinations are performed at baseline,4 w,8w and 12 w after treatment.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Budesonide nasal spray | Active Comparator | Budesonide nasal spray ,64mcg/putt,1 spray/nostril, 2 times/day,for 12 consecutive weeks. |
|
| Placebo | Placebo Comparator | Placebo:nasal placebo spray,1spray/nostril, 2 times/day,for 12 consecutive weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Budesonide nasal spray | Drug | 64mcg/1putt, 1 putt/nostril,b.i.d |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline fractional exhaled nitric oxide (FeNO) at 3 months | Fractional exhaled nitric oxide (FeNO) measured at 0 w,4 w,8 w and 12 w after treatment | 3 months after treatment |
| Change from baseline eosinophils in sputum at 3 months | Eosinophils in sputum at measured at 0 w,4 w,8 w and 12 w after treatment | 3 months after treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Changes of lower airway resistance (Z5,R5,X5,R5-20,R20 and Fres) using impulse oscillation | 0 w,4 w,8 w and 12 w after treatment | |
| Change of upper airway inflammation biomarker such as eosinophils in nasal lavage | 0 w,4 w,8 w and 12 w after treatment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nanshanzhong Zhong, master | Guangzhou Institute of Respiratory Disease | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Guangzhou institute of respiratory disease | Guangzhou | Guangdong | 510120 | China |
Not provided
| ID | Term |
|---|---|
| D065631 | Rhinitis, Allergic |
| D007249 | Inflammation |
| D012140 | Respiratory Tract Diseases |
| D006967 | Hypersensitivity |
| ID | Term |
|---|---|
| D012220 | Rhinitis |
| D009668 | Nose Diseases |
| D012130 | Respiratory Hypersensitivity |
| D010038 | Otorhinolaryngologic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | 1 putt/nostril,b.i.d |
|
|
| Change of cumulative dosage of methacholine causing a 20% fall in forced expiratory volume in 1 second (PD20FEV1-MCH) | 0 w,4 w,8 w and 12 w after treatment |
| To measure the differences in nasal symptoms score (TSS) about groups after 12 weeks of therapy | The parameters considered in the TSS were: nasal obstruction, sneezing, nasal discharge ,itching. These symptoms were scored: 0 = symptom absent, 1 = mild (symptoms present but not annoying), 2 = moderate (frequent and offensive symptoms but do not interfere with sleep or normal activities) 3 = severe (symptoms that interfere with sleep or normal activities). | 0 w,4 w,8 w and 12 w after treatment |
| The change in visual analogue scale score for symptoms of rhinitis | 0 w,4 w,8 w and 12 w after treatment |
| Juniper mini RQLQ | 0 w,4 w,8 w and 12 w after treatment |
| Change in levels of eosinophil（ECP），eosinophil peroxidase（EPO）, myeloperoxidase （MPO）and eosinophil-derived neurotoxin (EDN) in induced sputum and serum about groups after twelve weeks of therapy | At baseline and 12 w after treatment |
| Change in forced vital capacity (FVC) , in forced expiratory volume in 1 second (FEV1)，in forced expired flow at 25% of FVC(FEF25) and in forced expired flow at 75% of FVC (FEF75) about groups after twelve weeks of therapy. | 0 w,4 w,8 w and 12 w after treatment |
| Evaluation of the possible association between upper airway inflammation (eosinophil count in nasal lavage) and bronchial (PD20FEV1-MCH，FeNO and eosinophil count in induced sputum). | At the inclusion visit |
| D006969 |
| Hypersensitivity, Immediate |
| D007154 | Immune System Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |